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Background: Failure of locoregional control is the main cause of recurrence in advanced head and neck cancer.
This multi-center trial aims to improve outcome in two ways. Firstly, by redistribution of the radiation dose to the
metabolically most FDG-PET avid part of the tumour. Hereby, a biologically more effective dose distribution might
be achieved while simultaneously sparing normal tissues. Secondly, by improving patient selection. Both cisplatin
and Epidermal Growth Factor Receptor (EGFR) antibodies like Cetuximab in combination with Radiotherapy (RT) are
effective in enhancing tumour response. However, it is unknown which patients will benefit from either agent in
combination with irradiation. We will analyze the predictive value of biological markers and 89Zr-Cetuximab uptake
for treatment outcome of chemoradiation with Cetuximab or cisplatin to improve patient selection.
Methods: ARTFORCE is a randomized phase II trial for 268 patients with a factorial 2 by 2 design: cisplatin versus
Cetuximab and standard RT versus redistributed RT. Cisplatin is dosed weekly 40 mg/m2 for 6 weeks. Cetuximab is
dosed 250mg/m2 weekly (loading dose 400 mg/m2) for 6 weeks. The standard RT regimen consists of elective RT
up to 54.25 Gy with a simultaneous integrated boost (SIB) to 70 Gy in 35 fractions in 6 weeks. Redistributed
adaptive RT consists of elective RT up to 54.25 Gy with a SIB between 64-80 Gy in 35 fractions in 6 weeks with
redistributed dose to the gross tumour volume (GTV) and clinical target volume (CTV), and adaptation of treatment
for anatomical changes in the third week of treatment.
Patients with locally advanced, biopsy confirmed squamous cell carcinoma of the oropharynx, oral cavity or
hypopharynx are eligible.
Primary endpoints are: locoregional recurrence free survival at 2 years, correlation of the median 89Zr-cetuximab
uptake and biological markers with treatment specific outcome, and toxicity. Secondary endpoints are quality of
life, swallowing function preservation, progression free and overall survival.
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Discussion: The objective of the ARTFORCE Head and Neck trial is to determine the predictive value of biological
markers and 89Zr-Cetuximab uptake, as it is unknown how to select patients for the appropriate concurrent agent. Also
we will determine if adaptive RT and dose redistribution improve locoregional control without increasing toxicity.
ClinicalTrials.gov Identifier: NCT01504815
Keywords: Head and neck, Squamous cell carcinoma, Adaptive radiotherapy, Dose painting, Zirconium, Cetuximab,
CisplatinBackground
At diagnosis, 60% of the patients with head and neck
cancer have locally advanced disease, requiring multi-
modality treatment. For resectable disease, this treatment
consists of surgery and radiotherapy (RT) with or without
chemotherapy. For irresectable disease, the combination
of radiotherapy and chemotherapy (chemoradiotherapy) is
the treatment of choice. Chemoradiotherapy for head and
neck cancer typically entails radiotherapy of the tumour
and areas at risk for sub-clinical disease up to 70 Gy in
combination with the chemotherapeutic agent cisplatin in
different dose schemes. [1] Squamous cell carcinoma of
the head and neck (SCCHN) unfortunately still has a poor
prognosis, which is mainly due to failure of locoregional
control. [1] Improving locoregional control for patients
with locally advanced head and neck cancer is the objective
of our study.
This study is part of a large European research project
which investigates Adaptive and innovative Radiation
Treatment FOR improving Cancer treatment outcomE
(ARTFORCE). In this study, patients are randomized (a)
between standard radiotherapy and adaptive radiotherapy
combined with redistribution through dose-painting, and
(b) between concurrent treatment with either Cetuximab
or cisplatin. The following considerations have contributed
to this concept.
Firstly, analyses of locoregional recurrence patterns show
failure predominantly inside the gross tumour volume
(GTV) of the primary tumour. [2] We therefore proposed
to increase the dose to the most active part of the GTV
primary as shown on F-18-fluorodeoxyglucose- positron
emission tomography (FDG-PET) scan. [3] The dose is
only increased in the primary tumour, because persistent
neck nodes are salvable with surgery. Preliminary results
indicate feasibility of focal dose escalation to the FDG-
PET positive region, with acceptable toxicity. [4] Further-
more, adaptive replanning to account for anatomical
changes that occur during the irradiation period effectively
improves the sparing of organs at risk [5]. Hence, in the
ARTFORCE trial, we will randomize patients for either
the standard radiotherapy regimen (aiming to deliver a
homogeneous dose of 70 Gy to the primary tumour) or a
dose-painted - redistributed dose. In the dose-paintedredistribution radiotherapy regimen, first the region of the
primary tumour with at least 50% of its maximum FDG
uptake is defined. Subsequently, a heterogeneous dose
distribution is optimized aiming to deliver a maximum
dose of 84 Gy to the high FDG uptake region and at
least 64 Gy to the primary tumour (Figure 1). Adaptive
re-planning occurs after the second week of treatment.
This way, highly individualized radiotherapy can be
prescribed.
Secondly, cisplatin is not the only possible agent suited
for concurrent treatment. The use of Epidermal Growth
Factor Receptor (EGFR) antibodies such as Cetuximab,
for instance, is known to lead to similar results. [6,7]
Even though the results of treatment with cisplatin and
Cetuximab are comparable, it is not likely that these agents
are equally effective in all patients, e.g. most patients will be
cured by either treatment, yet some only by one. Treatment
outcome might thus be improved by selecting the right
drug for each patient. Currently, however, it is still un-
known how to determine which treatment is optimal for
which patient.
In this trial we evaluate the predictive value of biomarkers
and pre-treatment in vivo uptake of Cetuximab in the
tumour using zirconium-labelled (89Zr –labelled) Cetuximab
on a PET scan [8,9].
To summarize: this article describes the ARTFORCE
head & neck study protocol. ARTFORCE is a randomized
multi-centre phase II trial with a factorial 2 by 2 design.
In this study, standard radiotherapy is compared to
redistributed adaptive radiotherapy with regard to
locoregional control, disease free survival and toxicity.
Frozen tumour biopsies and blood are collected for
biomarkers and 89Zr-Cetuximab scans are performed to
evaluate their predictive value in allocating patients for
chemoradiotherapy with either concurrent Cetuximab
or cisplatin.
Study objectives and endpoints
Objectives:
 To determine if adaptive RT and dose
redistribution improve locoregional control
without increasing toxicity.
Figure 1 Dose in the redistributed radiotherapy regimen. Transverse (left) and coronal (right) view with isodose lines. In the dose-painted
redistriburtion radiotherapy regimen, the GTV-FDG-PET is defined by an automatic iso-contour at 50% of the maximum uptake in the primary
tumour. This is expanded by 3mm to form the PTV-FDG-PET. The GTV-primary should at least encompass the GTV-FDG-PET and is expanded by
10mm to form the PTV-primary. The PTV-FDG-PET will receive 35 fractions to a maximum total dose of 84 Gy to 2% of the volume (PTV-FDG-PET),
a minimum dose of 70 Gy and a mean dose of approximately 77 Gy. The PTV-primary outside the PTV-FDG-PET will receive 35 fractions to a total
mean dose of 67 Gy (ranging from 64-70 Gy).
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markers predict treatment specific outcome.
Primary endpoints
a. Locoregional recurrence free survival at 2 years
b.Correlation of the median 89Zr-Cetuximab uptake and
biological markers with treatment specific outcome
c. Toxicity
Secondary endpoints
d.Quality of life after treatment, at 6 months and 1 year
e. Swallowing function preservation at 1 year
f. Progression Free Survival
g. Overall SurvivalMethods
Study design
This study has a 2 by 2 design in which conventional
versus redistributed radiotherapy are compared, as well
as cisplatin versus Cetuximab (Figure 2). This leads to 4
different treatment arms. The first arm is considered
the standard treatment: conventional radiotherapy with
concomitant cisplatin. The second arm entails dose
redistributed adaptive radiotherapy with concomitant
cisplatin. Arm 3 and 4 both have Cetuximab regimens,
the former combined with standard radiotherapy, the
latter with redistributed adaptive radiotherapy.Sample size estimation
Sample size estimations are based on the comparison
between conventional and redistributed radiotherapy.
The study was designed to detect a 15% improvement in
locoregional control with a power of 80% at a signifi-
cance level of 0.05. The current locoregional recurrence
rate at two years was estimated to be 35%. To achieve
this significance level, 74 events need to be observed.
Based on four years of accrual, and 1 year of follow up,
268 patients need to be included.In- and exclusion criteria
Prior to treatment, all patients are clinically evaluated
by a multidisciplinary team consisting of at least a head
and neck surgeon, radiation-oncologist and a medical-
oncologist. Patients with histological proven stage III-IV,
T3 - T4 squamous cell carcinoma of the head and neck
are eligible for this trial and can be randomized after
informed consent. Age limitations are set between 18 and
70 years. Patients need to be fit for chemoradiotherapy
with a performance status 0–1 according to the World
Health Organization (WHO) classification.
The main exclusion criteria are previous malignancies,
prior treatment (surgery, chemotherapy or radiotherapy)
for this tumour and/or active bacterial or viral infection.Pre-treatment evaluation
Standard pretreatment evaluation includes a FDG-PET-CT,
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Figure 2 The ARTFORCE head & neck study design. (“tumour other” = tumour - 'tumour 50% isocontour PET’).
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needle aspiration (FNAC) in case of suspicious nodes,
electrocardiogram, audiometry and laboratory assess-
ment. HPV status determination for oropharynx carcin-
oma is mandatory, as well as an investigation under
general anesthesia with tumour biopsy. Extra for this study
are the collection of blood samples and a frozen biopsy for
biomarkers. Swallowing video fluoroscopy is optional.
Stratification will be done for tumour stage, tumour
site (oral cavity vs oropharynx vs hypopharynx), primary
tumour volume (< 30 cc vs 30 cc and above) and HPV-
status for oropharynx carcinoma.
Interventions
Pre-treatment 89Zr-Cetuximab scan
A week before the start of treatment a loading dose of
Cetuximab 400mg/m2 will be administered and immedi-
ately followed by the intravenous (i.v.) administration of
Zirconium labelled Cetuximab (89Zr-Cetuximab) (60mBq).
The first 30 patients will be scanned twice to determine
the optimal scanning moment to determine Cetuximab
uptake in the tumour. (Figure 3 and Figure 4). These
(89Zr-Cetuximab-PET) scans will be made 4 and 7 days
after 89Zr-Cetuximab administration. For the rest of the
study population we will select only one time moment for
the 89Zr-Cetuximab-PET. The aortic arch will also be
scanned and will serve as a reference point for 89Zr-
Cetuximab uptake.Treatment: radiotherapy regimens
The clinical target volume (CTV) around the primary
tumour is defined as the gross tumour volume (GTV) +
3D margin of 10mm, adjusted for anatomical borders in
which microscopic disease is unlikely to extend. The CTV
around the pathological lymph nodes is defined as the
gross GTV + 3D margin of 5mm, adjusted for anatomical
borders in which microscopic disease is unlikely to extend.
Elective lymph node regions are defined in the protocol
based on tumour site and stage, delineation should be
done according to published guidelines [10,11]. Planning
Target Volumes (PTV) are constructed by extension of
the CTV with a 3D margin of 3-5mm according to hos-
pital policy. The PTV will be irradiated with external
beam radiotherapy using intensity modulated radiotherapy
(IMRT) or Volumetric Modulated Arc Therapy (VMAT/
Rapid Arc) techniques. A simultaneous integrated boost
(SIB) technique will be used. Six fractions per week will be
given. The 6th fraction shall be given as a second fraction
on one of the weekdays with an interval of at least 6 hours.
Overall treatment time will be 39–40 days. Daily cone
beam CT scans will be made during treatment to verify
correct positioning of the patient before RT. Finally, daily
Electronic Portal Imaging Device (EPID) dosimetry will be
used for verification of actual radiation dose. Instructions
on dose prescription and margins, as well as dose
restrictions and delineation guidelines for organs at risk
are available online at http://www.cancerartforce.eu.
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Figure 3 89Zr-Cetuximab timeline. Day −3 is three days before the first day of treatment. Between day −14 and −7, further pre-treatment
evaluation is performed and the treatment planning is finalized.
Figure 4 Tumour imaging: FDG-PET/CT scans and 89Zr-Cetuximab-PET scans. A + B: patient with a negative 89Zr-Cetuximab scan. C + D:
patient with a positive 89Zr-Cetuximab scan.
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The standard radiotherapy regimen consists of 35
fractions of 2.0 Gy to a total dose of 70 Gy to the PTVs
of the primary tumour and the affected lymph nodes.
The PTV elective lymph nodes will receive 35 fractions
of 1.55 Gy to a total dose of 54.25 Gy.
Redistributed adaptive radiotherapy
In the dose-painted redistriburtion radiotherapy regi-
men, the GTV-FDG-PET is defined by an automatic iso-
contour at 50% of the maximum uptake in the primary
tumour. This is expanded by 3mm to form the PTV-
FDG-PET. The GTV-primary should at least encompass
the GTV-FDG-PET and is expanded by 10mm to form
the PTV-primary, as described earlier.
The PTV-FDG-PET will receive 35 fractions to a max-
imum total dose of 84 Gy to 2% of the volume (PTV-
FDG-PET), a minimum dose of 70 Gy and a mean dose
of approximately 77 Gy. The PTV-primary outside the
PTV-FDG-PET will receive 35 fractions to a total mean
dose of 67 Gy (ranging from 64-70 Gy).
To assure accurate delivery of the redistributed radi-
ation plan in arm 2 and 4, a repeat CT is made in week
2 of treatment. After recalculation and adaptation of the
treatment plan on this CT, the patient will start with
the new plan in week 3 of treatment. This way, we can
account for anatomical changes thereby improving the
accuracy of the dose delivery and sparing organs at risk.
Treatment: concomitant strategies
Cisplatin treatment
Cisplatin treatment consists of weekly administration
of cisplatin 40mg/m2 intravenously (i.v.) for 6 weeks.
All cisplatin doses are accompanied by pre- and post-
hydration with 2.5L of fluids according to the institu-
tional standards of practice to minimize the risk of
renal damage. Anti-emetic medication will be given
according to hospital standards.
Cetuximab treatment
Cetuximab treatment (250mg/m2 i.v.) is given weekly for 6
weeks. An infusion of Cetuximab is always preceded by an
antihistamine and corticosteroid to prevent allergic
reactions.[12] Also, patients receiving Cetuximab treatment are
prescribed doxycycline and pre-emptive topical treatment
i.e. skin moisturizers, sunscreen and topical steroid to pre-
vent skin toxicity according to Lacouture et al. [13].
Results
Assessment of toxicity
Toxicity is scored at least weekly according to the com-
mon toxicity criteria for adverse effects (CTCAE) ver-
sion 4.0. [14] Electronic Case Report Forms will be used
to document toxicity. Quality of life is scored using theQuality of life questionnaire (QLQ)-C30 (version 3.0)
and the head and neck Cancer-specific QLQ-H&N35
and EuroQol-5D.
The study protocol has instructions (available online
at http://www.cancerartforce.eu) on dose reductions and
other measures to be undertaken in case of toxicity. It
also defines when treatment should be discontinued.
Follow up
Patients are examined weekly during treatment. Follow
up starts directly after treatment and continues once
weekly for 3 weeks. Thereafter, follow up visits are every
3 months for the first two years and twice annually until
at least 5 years of follow-up.
Response evaluation
The first evaluation is performed 12 weeks after the
end of treatment. Evaluation will consist of physical
examination, an FDG-PET, and either CT or MRI according
to hospital standard. If recurrence is suspected, US with
FNAC and examination under anesthesia with biopsy shall
be performed. The response will be classified according to




The study will be conducted according to the ICH
Harmonized Tripartite Guideline for Good Clinical Prac-
tice. It will be conducted in agreement with the declar-
ation of Helsinki. The study has been approved by the
Medical Ethical Committee of the Netherlands Cancer
Institute - Antoni van Leeuwenhoek Hospital. Before the
start in other centers, the protocol will be approved by
local medical ethical committees.
All patients are given oral and written information
about the study. They are given sufficient time to con-
sider participating. Randomization will be done after
informed consent has been signed.
Quality assurance
Quality assurance in this trial is important and has the
following aspects. Delineation and treatment planning
guidelines are described in the protocol to ensure uni-
formity between centers. These guidelines were discussed
with all participants and consensus was reached. Subse-
quently, a contouring and planning dummy run was
performed by all participating centers, using a contouring
atlas and specific treatment planning guidelines. Feedback
was given after discussion in a group of trained specialists
at Netherlands Cancer Institute.
Furthermore, quality of imaging was assured by a
dummy run in all centers. For FDG-PET this included a
dummy run of phantom imaging, signal quantification,
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this included transport of the radiolabelled product,
imaging and signal quantification evaluation. Verifica-
tion of 89Zr-Cetuximab quantification as well as 89Zr-
Cetuximab PET scans on phantoms were performed by
the VU medical centre, a centre with extensive experience
in radiolabelling of drugs and image quality assurance.
Side studies
Tumour biopsies and blood samples from patients in
the head and neck trial will be studied for validation of
the response–predictive value of various biomarkers.
For instance, the genomic signature of the tumour ma-
terial will be investigated. Also, biomarkers such as the
“Chung profile”, human papilloma virus (HPV) status,
EGFR status and CD44 expression will be assessed. Fur-
thermore, the accumulated dose based on daily CBCT
scans and EPID dosimetry will be used in Tumour Con-
trol Probability (TCP) / Normal Tissue Complication
Probability (NTCP) studies [16-22].
Current status
The participating institutes include The Netherlands
Cancer Institute in Amsterdam, The Netherlands, and
Maastro Clinics in Maastricht, The Netherlands. Other
consortium partners, for which patient accrual will start
at a later phase include: Institut Gustave Roussy in Paris,
France, Karolinska Hospital in Stockholm, Sweden, Christie
Hospital in Manchester, United Kingdom, Val d’hebron
Hopital in Barcelona, Spain, The first patient started treat-
ment in September 2012. Patient accrual is expected to
continue for 4 years.
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